How should a type B aortic dissection distal to the left subclavian artery without ascending aorta involvement be treated?

Treatment of Type B Aortic Dissection

For uncomplicated type B aortic dissection (distal to the left subclavian artery without ascending aorta involvement), initial medical management with aggressive blood pressure and heart rate control is the standard of care, with TEVAR considered in the subacute phase (14-90 days) for selected patients with high-risk features. 1

Initial Management: Medical Therapy (Class I Recommendation)

All patients with type B aortic dissection require immediate medical management regardless of whether they ultimately receive intervention. 1

Blood Pressure Control

• Target systolic blood pressure <120 mmHg with aggressive antihypertensive therapy 2
• Beta-blockers are first-line agents to reduce aortic wall stress and heart rate 1, 2
• Most patients require combination antihypertensive therapy to achieve adequate control 2
• Pain relief is mandatory as part of initial management 1

Surveillance During Acute Phase

• Careful clinical and imaging monitoring is required during initial hospitalization 1
• Repeat imaging should assess for complications including expansion, periaortic hematoma, or malperfusion 1

Distinguishing Complicated from Uncomplicated Dissection

This distinction is critical as it fundamentally changes management strategy.

Complicated Type B Dissection (Requires Intervention)

TEVAR is recommended (Class I) for complicated type B dissection. 1

Complicated features include:

• Malperfusion syndromes (visceral, renal, limb) 1
• Rupture or impending rupture (periaortic hematoma) 1
• Refractory or recurrent pain despite medical therapy 1
• Rapid aortic expansion 1
• Uncontrolled hypertension despite maximal medical therapy 1

Uncomplicated Type B Dissection (Initial Medical Management)

For uncomplicated acute type B dissection, initial medical therapy under careful surveillance is recommended (Class I). 1

However, TEVAR in the subacute phase (between 14 and 90 days) should be considered (Class IIa) in selected patients with high-risk features to prevent aortic complications. 1

High-Risk Features Warranting Consideration of Subacute TEVAR

Even in initially uncomplicated dissections, certain imaging features predict worse outcomes:

• Large false lumen diameter with active flow 2
• Complete thrombosis of false lumen is protective; patent false lumen predicts progressive dilatation 2
• Partial thrombosis of false lumen 1
• Maximum aortic diameter >40 mm 1
• Entry tear >10 mm 1

The 2024 ESC guidelines represent an evolution from purely medical management, now recommending consideration of prophylactic TEVAR in the subacute window for high-risk uncomplicated cases. 1

Long-Term Management and Surveillance

Imaging Follow-Up Protocol

For medically treated type B dissection, follow-up imaging is recommended at 1,3,6, and 12 months after onset, then yearly if imaging findings are stable (Class I). 1

• MRI is preferred for serial follow-up to avoid radiation and contrast exposure 2
• Annual surveillance continues indefinitely as late complications can occur after many years 2

Indications for Delayed Intervention in Chronic Type B Dissection

In chronic type B dissection with descending thoracic aortic diameter ≥60 mm, treatment is recommended in patients at reasonable surgical risk (Class I). 1

For descending thoracic aortic diameter ≥55 mm, intervention should be considered in patients with low procedural risk (Class IIa). 1

Long-Term Medical Therapy

• Lifelong antihypertensive therapy is mandatory (Class I) 1, 2
• Beta-blockers remain first-line agents 2
• Statin therapy may improve survival 2
• Moderate physical activity restriction is recommended 2

Critical Pitfalls to Avoid

Approximately 40% of chronic type B dissection patients eventually require intervention due to aortic dilatation, with the dissected aorta growing at approximately 1 mm per year. 2

With medical treatment alone for uncomplicated type B dissection, 30% develop aneurysmal degeneration and 10% mortality occurs over 5 years. 3

Up to 20-55% of medically treated patients develop aneurysmal degeneration after 5 years with unknown rupture risk. 4

Around 10% of patients develop complications requiring reoperation during long-term follow-up, emphasizing the need for lifelong surveillance. 2

Treatment Algorithm Summary

1. Immediate assessment: Determine if complicated or uncomplicated 1
2. All patients: Initiate aggressive medical therapy with beta-blockers and blood pressure control to target SBP <120 mmHg 1, 2
3. Complicated dissection: Proceed with TEVAR (Class I recommendation) 1
4. Uncomplicated dissection: Continue medical management with close surveillance 1
5. Subacute phase (14-90 days): Reassess for high-risk features and consider TEVAR (Class IIa) 1
6. Long-term: Lifelong medical therapy and imaging surveillance at specified intervals 1, 2
7. Chronic phase: Intervene if diameter reaches ≥60 mm (Class I) or ≥55 mm in low-risk patients (Class IIa) 1